AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$CRMD

CorMedix (CRMD) Q3 2026 Earnings Call Transcript

CorMedix (CRMD) announced a definitive agreement to acquire Heron Therapeutics' assets for $125M-$150M in 2027 revenue, expecting $45M-$60M in annual cost synergies. Q3 2026 revenue was $54.5M, with full-year guidance narrowed to $130M-$140M adjusted EBITDA. The company deferred 2027 DefenCath revenue guidance due to uncertainty around reimbursement.

Original reporting
finance.yahoo.com
Published Nov 12, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 6:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CorMedix (CRMD) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CRMDBearishHigh
01

Why it matters

The acquisition expands CorMedix's product portfolio, diversifies revenue, and narrows EBITDA guidance, likely prompting a positive stock reaction.

02

Market read

First report of a material acquisition and guidance update for a listed biotech, offering actionable insight for traders.

03

What to watch

Regulatory clearance risk and contingent payment structure tied to future sales could delay accretion.

Relevance 8/10Novelty 8/10Timing: post‑call today

Background

CorMedix's Q3 2026 earnings call covered operational performance, pipeline updates, and a major acquisition announcement.

Company-level read

Ticker impact

$CRMDBearishHigh confidence
Context

CorMedix announced a definitive agreement to acquire substantially all assets of Heron Therapeutics and provided updated 2026 revenue and EBITDA guidance.

Expected impact

likely upward pressure as market prices in the accretive deal and tighter EBITDA outlook

Evidence & confidence

Deal adds $125‑$150M of pro‑forma revenue and is expected to be immediately earnings‑accretive; guidance tightening signals confidence.

Market effects

Sector

Strengthens CorMedix's position in institutional acute‑care and oncology supportive‑care markets.

Regional

U.S. healthcare investors may re‑price similar niche biotech acquisition targets.

Global

Highlights continued consolidation in specialty drug space, may influence global biotech M&A sentiment.

Counterpoint

What could challenge this read

If integration costs exceed expectations, the deal could pressure margins despite revenue boost.

Key entities

  • Company
    CorMedix

    US‑listed biotech firm (ticker CRMD) reporting earnings and acquisition.

  • Company
    Heron Therapeutics

    Target of CorMedix's asset acquisition.

Read at source← All news

Also covered by

2 outlets

Related articles

$CRMDHighAI 8/10

What CorMedix (CRMD) Said on Its Q3 Earnings Call

CorMedix (CRMD) reported Q3 earnings, expecting 2027 Medicare add-on payments to average below $8.32 but at least twice the current rate. The company anticipates closing its Heron acquisition in Q1 2027, adding $125M-$150M in revenue. It also expects $45M-$60M in annual cost synergies. CorMedix has $355.2M in cash and narrowed its 2026 operating expense guidance to $140M-$145M. The FDA granted priority review for REZZAYO, with a decision expected in Q1 2027.

finance.yahoo.com
$CRMDMed

CorMedix Reports Q3 2026 Revenue of $54.5 Million and Net Loss of $14.7 Million

CorMedix reported Q3 2026 revenue of $54.5M, down from $104.3M YoY, and a net loss of $14.7M. Adjusted EBITDA was $3.1M. The company maintained full-year revenue guidance and narrowed adjusted EBITDA guidance. CorMedix agreed to acquire Heron's assets, expecting $125M-$150M in 2027 revenue. The FDA accepted a supplemental application for REZZAYO. DefenCath sales were affected by pricing changes.

tradingview.com
$CRMDHighAI 8/10

CORMEDIX THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Recently announced acquisition of assets of Heron Therapeutics ‒ ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA

SEC EDGAR 8-K
$CRMDMedAI 8/10

CorMedix to Acquire Heron Assets for $145M Cash, Stock and Up to $55M in Earn-Outs

CorMedix (CRMD) agreed to acquire Heron's assets for $145M in cash and stock, plus up to $55M in earn-outs. The deal includes four commercial products and a development pipeline, generating $150M in trailing 12-month revenue. CorMedix expects earnings accretion and $45M-$60M in annualized cost synergies by year-end 2027. The transaction is subject to approvals and expected to close in Q1 2027, according to the company.

tradingview.com